MidWestOne Financial Group Inc. Increases Position in Sanofi $SNY

MidWestOne Financial Group Inc. grew its holdings in Sanofi (NASDAQ:SNY) by 90.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,940 shares of the company’s stock after purchasing an additional 14,237 shares during the period. MidWestOne Financial Group Inc.’s holdings in Sanofi were worth $1,413,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SNY. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC raised its position in Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after buying an additional 347 shares during the period. Finally, Concurrent Investment Advisors LLC grew its position in shares of Sanofi by 26.0% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 12,226 shares of the company’s stock worth $591,000 after buying an additional 2,526 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue?adding move that supports longer?term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short?term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex?Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell?off and the stock trading near 52?week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near?term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short?term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Analyst Ratings Changes

Several analysts recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a report on Friday, January 16th. TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Five equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Trading Down 2.2%

NASDAQ SNY opened at $46.01 on Friday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a 50 day moving average price of $47.73 and a 200 day moving average price of $48.60. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market cap of $112.22 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 1.22 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.